ARGENX SE - ADR (ARGX) Fundamental Analysis & Valuation

NASDAQ:ARGX • US04016X1019

Current stock price

785.07 USD
+19.64 (+2.57%)
At close:
785.07 USD
0 (0%)
After Hours:

This ARGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. ARGX Profitability Analysis

1.1 Basic Checks

  • ARGX had positive earnings in the past year.
  • In multiple years ARGX reported negative net income over the last 5 years.
  • ARGX had a negative operating cash flow in each of the past 5 years.
ARGX Yearly Net Income VS EBIT VS OCF VS FCFARGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 18.01%, ARGX belongs to the best of the industry, outperforming 95.94% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 21.20%, ARGX belongs to the top of the industry, outperforming 95.74% of the companies in the same industry.
  • ARGX's Return On Invested Capital of 13.73% is amongst the best of the industry. ARGX outperforms 95.55% of its industry peers.
Industry RankSector Rank
ROA 18.01%
ROE 21.2%
ROIC 13.73%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARGX Yearly ROA, ROE, ROICARGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • ARGX has a better Profit Margin (31.12%) than 94.78% of its industry peers.
  • With an excellent Operating Margin value of 25.68%, ARGX belongs to the best of the industry, outperforming 94.39% of the companies in the same industry.
  • ARGX has a better Gross Margin (89.15%) than 90.91% of its industry peers.
  • In the last couple of years the Gross Margin of ARGX has remained more or less at the same level.
Industry RankSector Rank
OM 25.68%
PM (TTM) 31.12%
GM 89.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.34%
GM growth 5YN/A
ARGX Yearly Profit, Operating, Gross MarginsARGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ARGX Health Analysis

2.1 Basic Checks

  • ARGX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • ARGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ARGX Yearly Shares OutstandingARGX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ARGX Yearly Total Debt VS Total AssetsARGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • ARGX has an Altman-Z score of 28.85. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 28.85, ARGX belongs to the top of the industry, outperforming 92.26% of the companies in the same industry.
  • ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • ARGX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ARGX outperforms 47.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 28.85
ROIC/WACC1.85
WACC7.43%
ARGX Yearly LT Debt VS Equity VS FCFARGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
  • ARGX has a Current ratio (5.60) which is in line with its industry peers.
  • A Quick Ratio of 5.27 indicates that ARGX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.27, ARGX is in line with its industry, outperforming 58.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.27
ARGX Yearly Current Assets VS Current LiabilitesARGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. ARGX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1028.32% over the past year.
  • Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 89.56%.
  • ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 151.52% yearly.
EPS 1Y (TTM)1028.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%762.37%
Revenue 1Y (TTM)89.56%
Revenue growth 3Y116.21%
Revenue growth 5Y151.52%
Sales Q2Q%73.67%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.38% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 20.88% on average over the next years. This is a very strong growth
EPS Next Y42.94%
EPS Next 2Y35.43%
EPS Next 3Y35.35%
EPS Next 5Y30.38%
Revenue Next Year40.86%
Revenue Next 2Y30.98%
Revenue Next 3Y26.77%
Revenue Next 5Y20.88%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARGX Yearly Revenue VS EstimatesARGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
ARGX Yearly EPS VS EstimatesARGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 40 60 80 100

More info and screens

Find the best growth stocksShow best growing peers

4

4. ARGX Valuation Analysis

4.1 Price/Earnings Ratio

  • ARGX is valuated quite expensively with a Price/Earnings ratio of 37.47.
  • ARGX's Price/Earnings ratio is rather cheap when compared to the industry. ARGX is cheaper than 91.49% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.91, ARGX is valued a bit more expensive.
  • ARGX is valuated quite expensively with a Price/Forward Earnings ratio of 26.21.
  • Based on the Price/Forward Earnings ratio, ARGX is valued cheaper than 92.84% of the companies in the same industry.
  • ARGX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.69.
Industry RankSector Rank
PE 37.47
Fwd PE 26.21
ARGX Price Earnings VS Forward Price EarningsARGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX Per share dataARGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ARGX has a very decent profitability rating, which may justify a higher PE ratio.
  • ARGX's earnings are expected to grow with 35.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.87
PEG (5Y)N/A
EPS Next 2Y35.43%
EPS Next 3Y35.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARGX Dividend Analysis

5.1 Amount

  • ARGX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARGX Fundamentals: All Metrics, Ratios and Statistics

ARGENX SE - ADR

NASDAQ:ARGX (4/8/2026, 8:16:37 PM)

After market: 785.07 0 (0%)

785.07

+19.64 (+2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners44.15%
Inst Owner Change0%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap48.58B
Revenue(TTM)4.15B
Net Income(TTM)1.29B
Analysts84.8
Price Target1031.57 (31.4%)
Short Float %3.05%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.49%
Min EPS beat(2)18.63%
Max EPS beat(2)28.35%
EPS beat(4)4
Avg EPS beat(4)19.32%
Min EPS beat(4)7.11%
Max EPS beat(4)28.35%
EPS beat(8)6
Avg EPS beat(8)2001.87%
EPS beat(12)9
Avg EPS beat(12)1341.86%
EPS beat(16)12
Avg EPS beat(16)1013.44%
Revenue beat(2)2
Avg Revenue beat(2)3.6%
Min Revenue beat(2)0.3%
Max Revenue beat(2)6.9%
Revenue beat(4)3
Avg Revenue beat(4)3.64%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)4.53%
Revenue beat(12)10
Avg Revenue beat(12)6.69%
Revenue beat(16)14
Avg Revenue beat(16)21.96%
PT rev (1m)0%
PT rev (3m)6.05%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-15.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.97%
Revenue NQ rev (1m)-0.67%
Revenue NQ rev (3m)0.75%
Revenue NY rev (1m)1.4%
Revenue NY rev (3m)2.97%
Valuation
Industry RankSector Rank
PE 37.47
Fwd PE 26.21
P/S 11.7
P/FCF N/A
P/OCF N/A
P/B 7.97
P/tB 8.27
EV/EBITDA N/A
EPS(TTM)20.95
EY2.67%
EPS(NY)29.95
Fwd EY3.81%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS67.09
BVpS98.5
TBVpS94.97
PEG (NY)0.87
PEG (5Y)N/A
Graham Number215.48
Profitability
Industry RankSector Rank
ROA 18.01%
ROE 21.2%
ROCE 17.38%
ROIC 13.73%
ROICexc 38.19%
ROICexgc 42.4%
OM 25.68%
PM (TTM) 31.12%
GM 89.15%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.34%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.27
Altman-Z 28.85
F-ScoreN/A
WACC7.43%
ROIC/WACC1.85
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1028.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%762.37%
EPS Next Y42.94%
EPS Next 2Y35.43%
EPS Next 3Y35.35%
EPS Next 5Y30.38%
Revenue 1Y (TTM)89.56%
Revenue growth 3Y116.21%
Revenue growth 5Y151.52%
Sales Q2Q%73.67%
Revenue Next Year40.86%
Revenue Next 2Y30.98%
Revenue Next 3Y26.77%
Revenue Next 5Y20.88%
EBIT growth 1Y7710.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.31%
EBIT Next 3Y46.52%
EBIT Next 5Y34.92%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ARGENX SE - ADR / ARGX Fundamental Analysis FAQ

What is the fundamental rating for ARGX stock?

ChartMill assigns a fundamental rating of 5 / 10 to ARGX.


Can you provide the valuation status for ARGENX SE - ADR?

ChartMill assigns a valuation rating of 4 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.


What is the profitability of ARGX stock?

ARGENX SE - ADR (ARGX) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for ARGX stock?

The Price/Earnings (PE) ratio for ARGENX SE - ADR (ARGX) is 37.47 and the Price/Book (PB) ratio is 7.97.